1. Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome 
Yago Nieto, Uday Popat, Paolo Anderlini, Ben Valdez, Borje Andersson, Ping Liu, Chitra Hosing, Elizabeth J. Shpall, Amin Alousi, Partow Kebriaei, Muzaffar Qazilbash, Simrit Parmar, Qaiser Bashir, Nina Shah, Issa Khouri, Gabriela Rondon, Richard Champlin, Roy B. Jones 
Biology of Blood and Marrow Transplantation 
Volume 19, Issue 3, Pages (March 2013)
DOI: /j.bbmt
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Outcomes of cohorts of patients with refractory HL treated with Gem-Bu-Mel, Bu-Mel, or BEAM ( ). (A) EFS of the 3 groups. (B) EFS of Gem-Bu-Mel versus the combined Bu-Mel + BEAM groups (log-rank: P = .01, Cox proportional hazards regression: P = .0008). (C) OS of the 3 groups. (D) OS of Gem-Bu-Mel versus the combined Bu-Mel + BEAM groups (log-rank P = .04, Cox proportional hazards regression: P = .0005).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Prognostic analysis of EFS. (A) PET and disease status at the time of HDC (Gem-Bu-Mel cohort). (B) Number of prior lines of salvage therapy (Gem-Bu-Mel). (C) Prior exposure/response to gemcitabine (Gem-Bu-Mel). (D) Pre- and post-HDC PET (Gem-Bu-Mel). (E) Disease status at HDC (Gem-Bu-Mel). (F) Disease status at HDC (combined Bu-Mel + BEAM group).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
EFS comparisons across main patient subgroups. (A) Patients with PET-negative tumors at HDC. (B) Patients with PET-positive tumors. (C) Patients with 1 prior salvage treatment line. (D) Patients with >1 prior salvage treatment line.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2013 American Society for Blood and Marrow Transplantation Terms and Conditions